Answers are grounded in this paper and cite their sources.
Therapeutic proteins need to be produced in large quantities as they continuously gain higher shares in pharmaceutical market. Human beta interferon (hIFN-β) is used against different diseases due to its antiviral, antiproliferative and immunomodulatory nature. Considering its clinical applications, development of a simple, cost-effective and easily scalable production system to produce rhIFN-β-1b protein in high yield and quality is needed. Attempts to develop improved production methods are ongoing. Majority of previous reports propose isopropyl-β-D-1-thiogalactopyranoside (IPTG), for rhIFN-β-1b expression in Escherichia coli, which is costly and nonmetabolizable. Thus, in current study, rhIFN-β-1b expression was optimized in an inexpensive auto-induction medium. Corn steep liquor (CSL) was used and optimized at different concentrations. Further, the medium was also optimized for carbon sources using various glycerol concentrations. Finally, a 10 L fermentation batch was done (10% CSL and 2.5% glycerol) that produced 65 g of wet biomass and 15 g of inclusion body (wet). The purification scheme was optimized by one-step ion-exchange chromatography (IEX) for > 99% purity of the target protein. The biological activity of the required protein was assessed through cytopathic inhibition effect of virus vesicular stomatitis (VSV) on Madin-Darby bovine kidney (MDBK) cells. Moreover, cytotoxicity of the protein was also studied on different breast cancer cell lines; HCC- 1954, MCF- 7 and MDA- MB- 231. This is the first report on utilizing CSL as auto-induction media for expression and purification of rhIFN-β-1b. Thus, the suggested method can be employed for simple as well as cost-effective production of rhIFN-β-1b and other recombinant proteins.
No takes yet. Share an insight, caveat, or question.
Rafi et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: